Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer

Urologia Internationalis

Volumn 87, Issue 3, 2011, Pages 263-269

  Takaha, Natsuki ^a   Okihara, Koji ^a   Kamoi, Kazumi ^a   Hongo, Fumiya ^a   Iwata, Tsuyoshi ^a   Yano, Kimihiro ^a   Ueda, Takashi ^a   Takeuchi, Ichiro ^a   Yamada, Takeshi ^a   Kawauchi, Akihiro ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Castration resistant prostate cancer; Docetaxel; Dose intensity; Elderly patients; Relative dose intensity

Indexed keywords

ANTIEMETIC AGENT; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; GROUPS BY AGE; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERAL METASTASIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CASTRATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80055044565     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000328217     Document Type: Article

References (19)

1. Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, Kattan MW, Monfardini S, Moul JW, Naeim A, van Poppel H, Saad F, Sternberg CN: Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol 2010; 73: 68-91.
2. Misumi T, Yamamoto Y, Murakami T, Kawai Y, Ito H, Eguchi S, Yano S, Nagao K, Hara T, Sakano S, Naito K, Sasaki K, Fuellhase C, Arenas L, Fichtner J, Matsuyama H: Genetic alterations at 13q14 may correlate with differences in the biological behavior of prostate cancer between Japanese and Caucasian men. Urol Int 2010; 84: 461-466.
3. Cancer Registration Committee of The Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005; 12: 46-61.
4. Rodrigues P, Meler A, Hering F: Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: A prospective open-label study. Urol Int 2010; 85: 180-185.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
6. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245.
7. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
8. Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, Hoshi S, Akaza H: Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: A multicenter phase II trial in Japan. Jpn J Clin Oncol 2008; 38: 365-372.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383.
10. Miyoshi Y, Uemura H, Nakamura M, Hasumi H, Sugiura S, Makiyama K, Nakaigawa N, Kishida T, Ogawa T, Yao M, Kubota Y: Treatment of androgen-independent, hormonerefractory prostate cancer with docetaxel in Japanese patients. Int J Clin Oncol 2005; 10: 182-186.
11. Sella A, Sternberg CN, Skoneczna I, Kovel S: Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU Int 2008; 102: 1607-1609
12. Nelius T, Filleur S: PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy. Prostate 2009; 69: 1802-1807.
13. Shimazui T, Kawai K, Miyanaga N, Kojima T, Sekido N, Hinotsu S, Oikawa T, Joraku A, Akaza H: Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: A retrospective comparative study with weekly docetaxel alone. Jpn J Clin Oncol 2007; 37: 603-608.
14. Ide H, Kikuchi E, Kono H, Nagata H, Miyajima A, Nakagawa K, Ohigashi T, Nakashima J, Oya M: Docetaxel in combination with prednisolone for hormone refractory prostate cancer. Jpn J Clin Oncol 2010; 40: 79-84.
15. Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, Bompas E, Flechon A, Joly F, Ferrero JM, Fizazi K: Docetaxelbased chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009; 55: 1368-1375.
16. ten Tije AJ, Verweij J, Carducci MA, Graveland W, Rogers T, Pronk T, Verbruggen MP, Dawkins F, Baker SD: Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005; 23: 1070-1077.
17. Wang GS, Yang KY, Perng RP: Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer 2001; 85: 1247-1250.
18. Morris MJ, Santamauro J, Shia J, Schwartz L, Vander Els N, Kelly K, Scher H: Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. Urology 2002; 60: 1111vi-1111ix.
19. Read WL, Mortimer JE, Picus J: Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002; 94: 847-853.